DC
INDV icon

Diametric Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Diametric Capital’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,838
Closed -$475K – 357
2025
Q1 		$475K Buy
49,838
+19,351
+63% +$203K 0.56% 52
2024
Q4 		$391K Sell
30,487
-35,423
-54% -$364K 0.26% 108
2024
Q3 		$651K Sell
65,910
-8,678
-12% -$102K 0.32% 89
2024
Q2 		$1.17M Buy
74,588
+13,510
+22% +$244K 0.63% 34
2024
Q1 		$1.31M Buy
61,078
+35,028
+134% +$658K 0.73% 28
2023
Q4 		$394K Sell
26,050
-21,408
-45% -$380K 0.24% 137
2023
Q3 		$1.03M Sell
47,458
-9,009
-16% -$205K 0.43% 57
2023
Q2 		$1.31M Buy
+56,467
New +$1.29M 0.58% 45

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Diametric Capital's INDV Position: Q2 2025 in Review

Diametric Capital sold out of Indivior Pharmaceuticals (INDV) in Q2 2025, closing a stake of 49,838 shares — an estimated $475K sold.

Diametric Capital first reported a position in INDV in Q2 2023 and held it in 8 quarters. The position peaked at $1.31M in Q2 2023. 120 funds tracked by Wall St. Rank hold INDV as of Q2 2025.

  • Diametric Capital reported no remaining Indivior Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Diametric Capital sold 49,838 Indivior Pharmaceuticals shares in Q2 2025, an estimated $475K.
  • Diametric Capital first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Diametric Capital's Indivior Pharmaceuticals position peaked at $1.31M in Q2 2023.
  • 120 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2025.

Based on Diametric Capital's 13F filing for Q2 2025, filed 13 Aug 2025.